Apellis Pharmaceuticals Inc

222 articles about Apellis Pharmaceuticals Inc

• Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™

  6/26/2018

  Apellis Pharmaceuticals Inc. announced that it has commenced its PEGASUS Phase 3 trial assessing the safety and efficacy of APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH) compared to eculizumab (Soliris™).

• Apellis Pharmaceuticals to Host R&D Day on June 26, 2018

  6/19/2018

  Apellis Pharmaceuticals, Inc. announced that it will host an R&D Day from 2:00 p.m. to 5:00 p.m. Eastern Time on June 26, 2018 in New York City.  

• Apellis Finalizes Phase III Clinical Trial Plans for Geographic Atrophy Treatment With APL-2

  12/21/2017

  The Phase 3 program, planned to begin in the second half of 2018, will consist of two identical 600-patient prospective, multicenter, randomized, double-masked, sham-injection controlled studies to assess the efficacy and safety of multiple intravitreal injections of APL-2 in patients with GA.

• Apellis Pharma Expands Management Team, Appoints Timothy Sullivan CFO

  12/19/2017

  Prior to joining as CFO, Sullivan was an observer on Apellis' board of directors for nearly three years while he was a Partner at AJU IB Investment, a venture capital firm, where he led the firm's investments in life sciences companies.

• Epidarex Capital Portfolio Company Apellis Pharmaceuticals Completes IPO

  11/14/2017

  Epidarex and its predecessor fund, MASA Life Science Ventures, were among the company's earliest backers, funding the development of the company's core technology shortly after its spin-out from the University of Pennsylvania.

• Apellis Pharmaceuticals Announces Closing of its Initial Public Offering

  11/14/2017

  The total gross proceeds to Apellis were approximately $150.0 million, before deducting underwriting discounts and commissions and expenses payable by Apellis.

• 

  Cancer Biotech Apellis Pharma Sets Terms for $150M IPO

  10/31/2017

  The Crestwood, KY-based company plans to raise $150M by offering 10.7 million shares at a price range of $13 to $15.

• Apellis Pharma's Eye Drug Meets Primary Endpoint in Mid-Stage Study

  8/24/2017

• Apellis Pharma Nabs $60 Million to Advance APL-2 into Phase III Trials

  8/10/2017

• Apellis Pharma Announces $60 Million Series E Financing

  8/10/2017

• Apellis Pharma Release: Positive Data From APL-2 Studies Show Rapid And Durable Improvements In LDH And Hemoglobin Levels

  6/29/2017

• Apellis Pharma Receives EMA Orphan Drug Designation For APL-2 In PNH

  5/9/2017

• Apellis Pharma Announces FDA Fast Track Designation For APL-2 In PNH

  12/20/2016

• Apellis Pharma Reports Positive Interim Results From Phase Ib Clinical Trials Of APL-2 In PNH

  12/2/2016

• Apellis Pharma To Present Safety And Efficacy Data From Clinical Trials Of APL-2 In PNH At December Scientific Meetings

  11/21/2016

• Apellis Pharma Announces Appointment Of Dr. Robert Kim As Chief Medical Officer

  8/8/2016

• Apellis Pharma Announces Positive Results From Phase 1 Clinical Trials Of APL-2, A C3 Complement Inhibitor

  6/23/2016

• Apellis Pharma Bags $47 Million Series D Financing

  2/12/2016

• Apellis Pharmaceuticals Announces Formation of Scientific Advisory Board

  7/15/2015

• Apellis Pharmaceuticals Enters Clinical Testing Phase In Its Age-Related Macular Degeneration Program

  2/10/2015